COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression

Last updated: May 6, 2024
Sponsor: University of California, Irvine
Overall Status: Trial Not Available

Phase

N/A

Condition

Covid-19

Treatment

COVID-19 Androgen Sensitivity Test (CoVAST)

Clinical Study ID

NCT04530500
20205907
  • Ages 18-90
  • Male
  • Accepts Healthy Volunteers

Study Summary

This research study will evaluate the association of Androgen Receptor (AR) gene expression and COVID-19 disease severity and mortality. The research procedure involves collection of a single saliva sample which will be mailed to the participants by the study team. This saliva will be used in a COVID-19 Androgen Sensitivity Test (CoVAST) which will detect AR gene expression. Eligible participants are males, at least 18 years or older, and have tested positive for COVID-19.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male over the age of 18
  • Laboratory confirmed SARS-CoV-2 infection
  • Able to give verbal informed consent

Exclusion

Exclusion Criteria:

  • Unable to give informed consent
  • Diagnosed with an additional respiratory co-infection
  • XXY males

Study Design

Treatment Group(s): 1
Primary Treatment: COVID-19 Androgen Sensitivity Test (CoVAST)
Phase:
Study Start date:
August 13, 2020
Estimated Completion Date:
December 01, 2023

Connect with a study center

  • Applied Biology, Inc

    Irvine, California 92614
    United States

    Site Not Available

  • University of California, Irvine - Dermatology Clinical Research

    Irvine, California 92697
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.